InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
0
T+90 hit rate
25%
T+90 mean return
-11.0%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Hamm John M., Chief Financial Officer. Officer active across 1 company, notably Cumberland Pharmaceuticals INC. Aggregated, 5 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €8k. Activity tracked since 23 November 2021. The latest transaction was disclosed on 16 March 2025 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations5 total
5,930 shares@ US$5.4631.7% of flowCommon StockSEC:0001628280-25-013513:0
445 shares@ US$1.810.8% of flowCommon StockSEC:0001214659-24-005208:0
352 shares@ US$1.670.6% of flowCommon StockSEC:0001214659-23-016106:0
20,000 shares@ US$2.590.058% mcap74.8% of flowCommon StockSEC:0001209191-22-026140:0
3,800 shares@ US$2.350.0097% mcap12.6% of flowCommon StockSEC:0001209191-21-067905:0
Canonical exit: 21 Feb 2022 (T+90)
5 of 5 declarations
About Hamm John M.
John M. Hamm is the Chief Financial Officer of CUMBERLAND PHARMACEUTICALS INC. He is responsible for the financial management of the company, including financial planning and financial reporting. Hamm plays a crucial role in Cumberland Pharmaceuticals' financial strategy, contributing to its stability and growth.
